journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://www.readbyqxmd.com/read/28508875/early-phase-clinical-trials-of-anticancer-agents-in-children-and-adolescents-an-itcc-perspective
#1
REVIEW
Lucas Moreno, Andrew D J Pearson, Xavier Paoletti, Irene Jimenez, Birgit Geoerger, Pamela R Kearns, C Michel Zwaan, Francois Doz, Andre Baruchel, Josef Vormoor, Michela Casanova, Stefan M Pfister, Bruce Morland, Gilles Vassal
In the past decade, the landscape of drug development in oncology has evolved dramatically; however, this paradigm shift remains to be adopted in early phase clinical trial designs for studies of molecularly targeted agents and immunotherapeutic agents in paediatric malignancies. In drug development, prioritization of drugs on the basis of knowledge of tumour biology, molecular 'drivers' of disease and a drug's mechanism of action, and therapeutic unmet needs are key elements; these aspects are relevant to early phase paediatric trials, in which molecular profiling is strongly encouraged...
May 16, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28508874/lung-cancer-tracing-tumour-evolution
#2
Diana Romero
No abstract text is available yet for this article.
May 16, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28485409/immunotherapy-nivolumab-keeps-hcc-in-check-and-opens-avenues-for-checkmate
#3
David Killock
No abstract text is available yet for this article.
May 9, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28440331/immunotherapy-does-adjuvant-ipilimumab-have-little-adverse-effect-on-quality-of-life
#4
Paul Lorigan, Adele C Green
No abstract text is available yet for this article.
April 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28440330/in-the-news-from-aacr-2017
#5
Peter Sidaway
No abstract text is available yet for this article.
April 25, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28397828/emt-cscs-and-drug-resistance-the-mechanistic-link-and-clinical-implications
#6
REVIEW
Tsukasa Shibue, Robert A Weinberg
The success of anticancer therapy is usually limited by the development of drug resistance. Such acquired resistance is driven, in part, by intratumoural heterogeneity - that is, the phenotypic diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely capable of seeding new tumours, has provided a framework for understanding one dimension of intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic basis for anticancer drug resistance...
April 11, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28397825/gynaecological-cancer-novel-molecular-subtypes-of-cervical-cancer-potential-clinical-consequences
#7
Chris J L M Meijer, Renske D M Steenbergen
No abstract text is available yet for this article.
April 11, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28374786/targeted-agents-and-immunotherapies-optimizing-outcomes-in-melanoma
#8
REVIEW
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long
Treatment options for patients with metastatic melanoma, and especially BRAF-mutant melanoma, have changed dramatically in the past 5 years, with the FDA approval of eight new therapeutic agents. During this period, the treatment paradigm for BRAF-mutant disease has evolved rapidly: the standard-of-care BRAF-targeted approach has shifted from single-agent BRAF inhibition to combination therapy with a BRAF and a MEK inhibitor. Concurrently, immunotherapy has transitioned from cytokine-based treatment to antibody-mediated blockade of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and, now, the programmed cell-death protein 1 (PD-1) immune checkpoints...
April 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28374784/targeting-c-met-in-gastrointestinal-tumours-rationale-opportunities-and-challenges
#9
REVIEW
Conor A Bradley, Manuel Salto-Tellez, Pierre Laurent-Puig, Alberto Bardelli, Christian Rolfo, Josep Tabernero, Hajrah A Khawaja, Mark Lawler, Patrick G Johnston, Sandra Van Schaeybroeck
Data from many preclinical studies, including those using cellular models of colorectal, gastric, gastro-oesophageal and gastro-oesophageal junction cancers, indicate that the hepatocyte growth factor (HGF)-hepatocyte growth factor receptor (c-MET) pathway is vital for the growth, survival and invasive potential of gastrointestinal cancers. Following the availability of data from these various studies, and data on c-MET expression as a biomarker that indicates a poor prognosis in patients with gastrointestinal cancer and increased c-MET expression, inhibitors targeting this pathway have entered the clinic in the past decade...
April 4, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28290489/charged-particle-therapy-in-cancer-clinical-uses-and-future-perspectives
#10
REVIEW
Marco Durante, Roberto Orecchia, Jay S Loeffler
Radiotherapy with high-energy charged particles has become an attractive therapeutic option for patients with several tumour types because this approach better spares healthy tissue from radiation than conventional photon therapy. The cost associated with the delivery of charged particles, however, is higher than that of even the most elaborate photon-delivery technologies. Reliable evidence of the relative cost-effectiveness of both modalities can only come from the results of randomized clinical trials. Thus, the hurdles that currently limit direct comparisons of these two approaches in clinical trials, especially those related to insurance coverage, should be removed...
March 14, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28252003/integrating-liquid-biopsies-into-the-management-of-cancer
#11
REVIEW
Giulia Siravegna, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
During cancer progression and treatment, multiple subclonal populations of tumour cells compete with one another, with selective pressures leading to the emergence of predominant subclones that replicate and spread most proficiently, and are least susceptible to treatment. At present, the molecular landscapes of solid tumours are established using surgical or biopsy tissue samples. Tissue-based tumour profiles are, however, subject to sampling bias, provide only a snapshot of tumour heterogeneity, and cannot be obtained repeatedly...
March 2, 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28466878/urological-cancer-vinflunine-is-an-effective-maintenance-therapy
#12
Peter Sidaway
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28466877/haematological-cancer-nivolumab-is-effective-in-pcnsl-and-ptl
#13
Peter Sidaway
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28466876/immunotherapy-combine-and-conquer-antiangiogenic-immunotherapy
#14
David Killock
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28466875/pancreatic-cancer-rock-inhibition-sensitizes-preclinical-models
#15
Peter Sidaway
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28466874/immunotherapy-a-car-t-cell-recipe-for-success
#16
Diana Romero
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28440333/immunotherapy-cul-til-vating-uveal-melanoma-regression
#17
Lisa Hutchinson
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28440332/immunotherapy-reinvigorated-t-cell-numbers-counterbalance-tumour-burden
#18
David Killock
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28397827/cns-cancer-new-chemoradiation-standard-for-elderly-patients-with-glioblastoma
#19
Lisa Hutchinson
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/28397826/immunotherapy-hiding-in-plain-sight-immune-escape-in-the-era-of-targeted-t-cell-based-immunotherapies
#20
Anthony F Daniyan, Renier J Brentjens
No abstract text is available yet for this article.
June 2017: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"